Therapeutic Potential of Tocopherol and Tocotrienol in Glaucoma Management

Glaucoma is a leading cause of irreversible blindness worldwide, primarily driven by progressive optic nerve damage often associated with elevated intraocular pressure (IOP). While conventional treatments aim to reduce IOP, they fail to address the neurodegenerative mechanisms and oxidative stress underlying disease progression. This review evaluates the therapeutic potential of vitamin E isoforms which mainly focuses on tocopherol and tocotrienol. A comprehensive literature search on PUBMED following PRISMA guidelines identified 35 relevant studies published between 1950 and October 2024. These studies include clinical trials, in vivo, and in vitro investigations focusing on the antioxidant, neuroprotective, and IOP-modulating effects of tocopherol and tocotrienol. Tocopherol, especially α-tocopherol, has shown mixed clinical efficacy but consistent support for enhancing ocular blood flow and retinal ganglion cell survival. Tocotrienol, despite lower bioavailability, demonstrates superior antioxidant activity and potential for targeted neuroprotection. Advancements in drug delivery systems, including nanoliposomes, nanoparticles, and contact lenses, have further enhanced the ocular bioavailability of these compounds. However, the current evidence remains limited, with only a small number of clinical studies and inconsistent outcomes reported. This highlights an important opportunity for future research to focus on well-designed, longitudinal clinical trials that can better elucidate the therapeutic potential and clinical relevance of tocopherol and tocotrienol in glaucoma management. This review may provide an initial brief idea on the integration of vitamin E derivatives as adjunctive therapies in glaucoma management toward neuroprotection and oxidative stress mitigation.